Journal of Bone and Mineral Metabolism

, Volume 21, Issue 6, pp 421–427

Effect of alendronate on bone mineral density and bone turnover in Thai postmenopausal osteoporosis

Authors

  • La-or Chailurkit
    • Department of Medicine, Ramathibodi HospitalMahidol University
  • Wallaya Jongjaroenprasert
    • Department of Medicine, Ramathibodi HospitalMahidol University
  • Sasithorn Rungbunnapun
    • Department of Medicine, Ramathibodi HospitalMahidol University
  • Boonsong Ongphiphadhanakul
    • Department of Medicine, Ramathibodi HospitalMahidol University
  • Sunee Sae-tung
    • Department of Medicine, Ramathibodi HospitalMahidol University
  • Rajata Rajatanavin
    • Department of Medicine, Ramathibodi HospitalMahidol University
Article

DOI: 10.1007/s00774-003-0438-2

Cite this article as:
Chailurkit, L., Jongjaroenprasert, W., Rungbunnapun, S. et al. J Bone Miner Metab (2003) 21: 421. doi:10.1007/s00774-003-0438-2

Abstract

Alendronate has recently been approved for the prevention and treatment of postmenopausal osteoporosis, and its efficacy has been demonstrated in many Western countries. Our present study was performed to evaluate the effect of alendronate on bone mineral density (BMD) and its tolerability in Thais. Eighty postmenopausal women with osteoporosis participated in this study. After giving informed consent, the subjects were randomly allocated either 10 mg alendronate or placebo in a double-blind fashion. All patients received a supplement of 500 mg elemental calcium daily. BMD at the lumbar spine, femoral neck, and distal forearm was measured at baseline and 6 and 12 months after treatment. Biochemical markers of bone resorption were determined at baseline and 6 months after treatment. Baseline characteristics were similar in both alendronate- and placebo-treated groups. Ten subjects discontinued the study. Of 70 subjects, 32 received 10 mg alendronate daily and the remaining subjects received placebo. At 1 year, BMD in the alendronate-treated group had increased from baseline by 9.2%, 4.6%, and 3.1% at lumbar spine, femoral neck, and distal forearm, respectively. These percentages were greater than those in controls (4.1%, 0.6%, and 1.0%, respectively). Urinary N-terminal telopeptide (NTx)-I and serum C-terminal telopeptide (CTx)-I levels decreased in both groups after 6 months of treatment. However, more reduction was demonstrated in the alendronate-treated group (71.9% vs. 28.4%, P ≪ 0.01, and 84.7% vs. 33.1%, P ≪ 0.01, respectively). Compliance with treatment and drug tolerability were good in both alendronate and placebo groups. We concluded that treatment with alendronate 10 mg daily for Thai postmenopausal women with osteoporosis significantly increased BMD at all skeletal sites and reduced biochemical markers of bone resorption. It was well tolerated without any serious side effects.

Key words

alendronatepostmenopausal osteoporosisbone mineral densitybiochemical markers of bone resorption

Copyright information

© Springer-Verlag Tokyo 2003